Malaria vaccines: prospects and reality;Vaccins contre le paludisme : perspectives et réalité

Medecine et Maladies Infectieuses

Volumn 36, Issue 8, 2006, Pages 414-422

  Rogier, C ^a   Orlandi Pradines, E ^a   Fusai T ^a   Pradines, B ^a   Briolant, S ^a   Almeras, L ^a  

^a SERVICE DE SANTÉ DES ARMÉES   (France)

Author keywords

Malaria; Vaccine

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; DRUMS REPEAT ANTIGEN; ERYTHROCYTE BINDING ANTIGEN; GLUTAMATE RICH PROTEIN; INOSITOL; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2S; MEROZOITE SURFACE PROTEIN 3; MEROZOITE SURFACE PROTEIN 4; MEROZOITE SURFACE PROTEIN 5; PARASITE ANTIGEN; PLACEBO; RHOPTRY ASSOCIATED PROTEIN; RING INFECTED ERYTHROCYTE SURFACE ANTIGEN; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; BRAIN MALARIA; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; HUMAN; INFECTION PREVENTION; MALARIA FALCIPARUM; NONHUMAN; PARASITE TRANSMISSION; PATHOPHYSIOLOGY; PREVENTIVE MEDICINE; SHORT SURVEY; VACCINATION; VACCINE PRODUCTION; ANIMAL; IMMUNOLOGY; MALARIA; PLASMODIUM; REVIEW;

ANIMALS; ANTIGENS, PROTOZOAN; CLINICAL TRIALS; HUMANS; MALARIA; MALARIA VACCINES; PLASMODIUM;

EID: 33748895852     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2006.05.016     Document Type: Short Survey

References (57)

1. Bruce-Chwatt L.J., and Zulueta J. The rise and fall of malaria in Europe (1980), Oxford University Press, Oxford
2. Barat L.M. Four malaria success stories: how malaria burden was successfully reduced in Brazil, Eritrea, India and Vietnam. Am. J. Trop. Med. Hyg. 74 1 (2006) 12-16
3. Trape J.F., Pison G., Spiegel A., Enel C., and Rogier C. Combating malaria in Africa. Trends Parasitol. 18 5 (2002) 224-230
4. Trape J.F., and Rogier C. Combating malaria morbidity and mortality by reducing transmission. Parasitol. Today 12 6 (1996) 236-240
5. Greenwood B. Malaria vaccines. Evaluation and implementation. Acta Trop. 95 3 (2005) 298-304
6. Genton B., Betuela I., Felger I., Al-Yaman F., Anders R.F., Saul A., et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J. Infect. Dis. 185 6 (2002) 820-827
7. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N. Engl. J. Med. 336 2 (1997) 86-91
8. Scheller L.F., and Azad A.F. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc. Natl. Acad. Sci. USA 92 9 (1995) 4066-4068
9. McGregor I.A. Mechanisms of acquired immunity and epidemiological patterns of antibody responses in malaria in man. Bull. World Health Organ. 50 (1974) 259-266
10. Rogier C., Ly A.B., Tall A., Cisse B., and Trape J.F. Plasmodium falciparum clinical malaria in Dielmo, a holoendemic area in Senegal: no influence of acquired immunity on initial symptomatology and severity of malaria attacks. Am. J. Trop. Med. Hyg. 60 3 (1999) 410-420
11. Rogier C. Paludisme de l'enfant en zone d'endémie : épidemiologie, acquisition d'une immunité et stratégies de lutte. Med. Trop. (Mars.) 63 4-5 (2003) 449-464
12. Cohen S., McGregor I.A., and Carrington S. Gamma globulin and acquired immunity to human malaria. Nature 192 (1961) 733-737
13. Edozien J.C., Gilles H.M., and Udeozo I.O.K. Adult and cord-blood gamma globulin and immunity to malaria in Nigerians. Lancet ii (1962) 951-955
14. Sabchareon A., Burnouf T., Ouattara D., Attanath P., Bouharoun-Tayoun H., Chantavanich P., et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am. J. Trop. Med. Hyg. 45 3 (1991) 297-308
15. Clyde D.F. Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies 1971-1975. Bull. World Health Organ. 35 (1990) 873-882
16. Clyde D.F., Most H., McCarthy V.C., and Vanderberg J.P. Immunization of man against sporozoite-induced falciparum malaria. Am. J. Med. Sci. 266 (1973) 169-177
17. Hoffman S.L., Goh L.M., Luke T.C., Schneider I., Le T.P., Doolan D.L., et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 185 8 (2002) 1155-1164
18. Kwiatkowski D., and Marsh K. Development of a malaria vaccine. Lancet 350 9092 (1997) 1696-1701
19. Stowers A.W., Cioce V., Shimp R.L., Lawson M., Hui G., Muratova O., et al. Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial. Infect. Immun. 69 3 (2001) 1536-1546
20. Kester K.E., McKinney D.A., Tornieporth N., Ockenhouse C.F., Heppner D.G., Hall T., et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J. Infect. Dis. 183 4 (2001) 640-647
21. Graves P., and Gelband H. Vaccines for preventing malaria. Cochrane Database Syst. Rev. 1 (2003) (CD000129)
22. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Milman J., et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364 9443 (2004) 1411-1420
23. Carter R., Mendis K.N., Miller L.H., Molineaux L., and Saul A. Malaria transmission-blocking vaccines--how can their development be supported?. Nat. Med. 6 3 (2000) 241-244
24. WHO. Portfolio of candidate malaria vaccines currently in development. 2005 [cited; Available from: http://www.who.int/vaccine_research/documents/en/malaria table.pdf.
25. Fairley N.H. Sidelights on malaria in man obtained by subinoculation experiments. Trans. R. Soc. Trop. Med. Hyg. 40 (1947) 621-676
26. Herrington D.A., Clyde D.F., Losonsky G., Cortesia M., Murphy J.R., Davis J., et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328 6127 (1987) 257-259
27. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Aide P., et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366 9502 (2005) 2012-2018
28. Bojang K.A., Milligan P.J., Pinder M., Vigneron L., Alloueche A., Kester K.E., et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358 9297 (2001) 1927-1934
29. Gordon D.M., McGovern T.W., Krzych U., Cohen J.C., Schneider I., LaChance R., et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171 6 (1995) 1576-1585
30. Snounou G., Gruner A.C., Muller-Graf C.D., Mazier D., and Renia L. The Plasmodium sporozoite survives RTS,S vaccination. Trends Parasitol. 21 10 (2005) 456-461
31. Hill A. Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat. Rev. Immunol. 6 (2006) 21-32
32. Gilbert S.C., Plebanski M., Harris S.J., Allsopp C.E., Thomas R., Layton G.T., et al. A protein particle vaccine containing multiple malaria epitopes. Nat. Biotechnol. 15 12 (1997) 1280-1284
33. Moorthy V.S., Imoukhuede E.B., Milligan P., Bojang K., Keating S., Kaye P., et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med 1 2 (2004) e33
34. Holder A.A., Guevara Patino J.A., Uthaipibull C., Syed S.E., Ling I.T., Scott-Finnigan T., et al. Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. Parassitologia 41 1-3 (1999) 409-414
35. Chang S.P., Case S.E., Gosnell W.L., Hashimoto A., Kramer K.J., Tam L.Q., et al. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect. Immun. 64 1 (1996) 253-261
36. Stowers A.W., Kennedy M.C., Keegan B.P., Saul A., Long C.A., and Miller L.H. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect. Immun. 70 12 (2002) 6961-6967
37. Kennedy M.C., Wang J., Zhang Y., Miles A.P., Chitsaz F., Saul A., et al. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect. Immun. 70 12 (2002) 6948-6960
38. Anders R.F., Crewther P.E., Edwards S., Margetts M., Matthew M.L., Pollock B., et al. Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine 16 2-3 (1998) 240-247
39. Saul A., Lawrence G., Allworth A., Elliott S., Anderson K., Rzepczyk C., et al. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant. Vaccine 23 23 (2005) 3076-3083
40. Malkin E.M., Diemert D.J., McArthur J.H., Perreault J.R., Miles A.P., Giersing B.K., et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect. Immun. 73 6 (2005) 3677-3685
41. Bai T., Becker M., Gupta A., Strike P., Murphy V.J., Anders R.F., et al. Structure of AMA1 from Plasmodium falciparum reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. Proc. Natl. Acad. Sci. USA 102 36 (2005) 12736-12741
42. Healer J., Murphy V., Hodder A.N., Masciantonio R., Gemmill A.W., Anders R.F., et al. Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum. Mol. Microbiol. 52 1 (2004) 159-168
43. Audran R., Cachat M., Lurati F., Soe S., Leroy O., Corradin G., et al. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect. Immun. 73 12 (2005) 8017-8026
44. Badell E., Oeuvray C., Moreno A., Soe S., van Rooijen N., Bouzidi A., et al. Human malaria in immunocompromised mice: an in vivo model to study defense mechanisms against Plasmodium falciparum. J. Exp. Med. 192 11 (2000) 1653-1660
45. Singh S., Soe S., Mejia J.P., Roussilhon C., Theisen M., Corradin G., et al. Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design. J. Infect. Dis. 190 5 (2004) 1010-1018
46. Arevalo-Herrera M., Solarte Y., Yasnot M.F., Castellanos A., Rincon A., Saul A., et al. Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein. Am. J. Trop. Med. Hyg. 73 5 Suppl (2005) 32-37
47. Arakawa T., Komesu A., Otsuki H., Sattabongkot J., Udomsangpetch R., Matsumoto Y., et al. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum. Infect. Immun. 73 11 (2005) 7375-7380
48. Malkin E.M., Durbin A.P., Diemert D.J., Sattabongkot J., Wu Y., Miura K., et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23 24 (2005) 3131-3138
49. Carter R. Transmission blocking malaria vaccines. Vaccine 19 17-19 (2001) 2309-2314
50. Hermsen C.C., de Vlas S.J., van Gemert G.J., Telgt D.S., Verhage D.F., and Sauerwein R.W. Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction. Am. J. Trop. Med. Hyg. 71 2 (2004) 196-201
51. Cheng Q., Lawrence G., Reed C., Stowers A., Ranford-Cartwright L., Creasey A., et al. Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines. Am. J. Trop. Med. Hyg. 57 4 (1997) 495-500
52. Rogier C., Henry M.C., and Spiegel A. Diagnostic des accès palustres en zone d'endémie : bases théoriques et implications pratiques. Med. Trop. (Mars.) 61 1 (2001) 27-46
53. Xiao L., Rafi-Janajreh A., Patterson P., Zhou Z., and Lal A.A. Adjuvants and malaria vaccine development. Chem. Immunol. 80 (2002) 343-365
54. Miller L.H., Saul A., and Mahanty S. Revisiting Freund's incomplete adjuvant for vaccines in the developing world. Trends Parasitol. 21 9 (2005) 412-414
55. Good M.F. Genetically modified Plasmodium highlights the potential of whole parasite vaccine strategies. Trends Immunol. 26 6 (2005) 295-297
56. Mueller A.K., Labaied M., Kappe S.H., and Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433 7022 (2005) 164-167
57. Pombo D.J., Lawrence G., Hirunpetcharat C., Rzepczyk C., Bryden M., Cloonan N., et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360 9333 (2002) 610-617